TY  - JOUR
AU  - Handke, Analena
AU  - Kesch, Claudia
AU  - Fendler, Wolfgang Peter
AU  - Telli, Tugce
AU  - Liu, Yang
AU  - Hakansson, Alexander
AU  - Davicioni, Elai
AU  - Hughes, Jason
AU  - Song, Hong
AU  - Lueckerath, Katharina
AU  - Herrmann, Ken
AU  - Hadaschik, Boris
AU  - Seifert, Robert
TI  - Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy.
JO  - Journal for ImmunoTherapy of Cancer
VL  - 11
IS  - 10
SN  - 2051-1426
CY  - London
PB  - BioMed Central
M1  - DKFZ-2023-02119
SP  - e007354
PY  - 2023
AB  - 177Lu-PSMA ([177Lu]Lutetium-PSMA-617) therapy is an effective treatment option for patients with prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer, but still shows a non-responder rate of approximately 30
KW  - Prostatic Neoplasms (Other)
KW  - Radiotherapy (Other)
KW  - Tumor Biomarkers (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37857524
DO  - DOI:10.1136/jitc-2023-007354
UR  - https://inrepo02.dkfz.de/record/284823
ER  -